Needham downgrades Boston Scientific to Hold into slowing 2025 growth

Needham analyst Mike Matson downgraded Boston Scientific (BSX) to Hold from Buy without a price target The firm expects the company’s electrophysiology business to “slow significantly” in 2025 and cause its overall revenue growth to slow. Needham also sees risk around Boston Scientific’s ACURATE trial results. While investor expectations for ACURATE are low, the trial results are a catalyst that could move the shares up or down by 5%-10%, contends the firm. With the shares above its prior price target Needham views Boston Scientific as fairly valued.